Sinew Pharma Inc. Attends 8th MASH Drug Development Summit and Presents Clinical Trial Results

Seizing a $950 Million Market Opportunity: Sinew Pharma's New Pain Relief Drug Achieves Primary and Secondary Endpoints in Phase I/II Clinical Trial

Sinew Pharma's New Acetaminophen with High Liver Safety (SNP-810) , Combined with a Non-addictive Potent Pain Relief, Achieves Primary and Secondary Endpoints in Phase I/II Clinical Trial

Sinew's Earnings Call - Chairman: SNP-810 is a Pain Reliever with High Liver Safety

Sinew Pharma's New Acetaminophen Pain Reliever has Completed Clinical Trials, Aiming to Replace the Existing Market